| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
11,360,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Hillstream BioPharma is engaged in the development of therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treating cancers. Co.'s product candidate is HSB-1216, an IMCD modulator, targeting solid tumors. Co.'s HSB-888, is a dual-loaded IMCD inducer coupled with its anthracycline analogue. Co.'s HSB-510 is a bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6. Co. owns HSB-114, which is a immunotherapeutic agent that delivers tumor necrosis factor-alpha gene into cancer cells.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
39,000 |
39,000 |
43,501 |
| Total Buy Value |
$0 |
$24,587 |
$24,587 |
$28,278 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Milby Randy |
CEO |
• • – |
2023-12-15 |
4 |
B |
$0.50 |
$14,587 |
D/D |
29,000 |
156,517 |
2.81 |
- |
|
| Milby Randy |
CEO |
• • – |
2023-11-30 |
4 |
B |
$1.00 |
$10,000 |
D/D |
10,000 |
127,517 |
2.81 |
- |
|
| Appajosyula Sireesh |
Director |
– • – |
2022-07-14 |
4 |
GA |
$0.00 |
$0 |
I/I |
7,576 |
7,576 |
|
- |
|
| Appajosyula Sireesh |
Director |
– • – |
2022-07-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
75,757 |
0 |
|
- |
|
| Milby Randy |
Chief Executive Officer |
• • • |
2022-06-17 |
4 |
B |
$0.78 |
$390 |
D/D |
500 |
2,937,940 |
3.15 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-06-06 |
4 |
B |
$0.67 |
$688 |
D/D |
1,000 |
2,938,540 |
2.73 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-06-01 |
4 |
B |
$0.94 |
$1 |
D/D |
1 |
2,937,540 |
2.73 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-05-25 |
4 |
B |
$0.77 |
$786 |
D/D |
1,000 |
2,937,539 |
2.73 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-05-20 |
4 |
B |
$0.89 |
$918 |
D/D |
1,000 |
2,936,539 |
2.73 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-05-19 |
4 |
B |
$0.90 |
$908 |
D/D |
1,000 |
2,935,539 |
2.73 |
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-04-18 |
4 |
OE |
$0.08 |
$24,342 |
D/D |
240,526 |
2,934,539 |
|
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
OE |
$3.20 |
$1,229,840 |
D/D |
384,325 |
2,157,050 |
|
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
OE |
$3.20 |
$834,157 |
D/D |
260,674 |
2,417,724 |
|
- |
|
| Milby Randy |
Chief Executive Officer |
• • – |
2022-01-14 |
4 |
OE |
$3.20 |
$884,125 |
D/D |
276,289 |
2,694,013 |
|
- |
|
| Mazur Leonard L |
Director |
– • – |
2022-01-14 |
4 |
B |
$4.00 |
$100,000 |
D/D |
25,000 |
123,733 |
2.39 |
- |
|
| Mazur Leonard L |
Director |
– • – |
2022-01-14 |
4 |
OE |
$3.20 |
$315,946 |
D/D |
98,733 |
98,733 |
|
- |
|
| Kaur Varinder |
10% Owner |
– – • |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
653,059 |
|
- |
|
| Milby Randy |
Chief Executive OfficerOfficer |
• • • |
2022-01-11 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,772,725 |
|
- |
|
| Kufe Llc |
10% Owner |
– – • |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
810,395 |
|
- |
|
| Appajosyula Sireesh |
Director |
– • – |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,047,979 |
|
- |
|
| Appajosyula Sireesh |
Director |
– • – |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
284,090 |
|
- |
|
| Highpoint Pharmaceuticals Llc |
10% Owner |
– – • |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
972,222 |
|
- |
|
| Kharbanda Surender |
10% Owner |
– – • |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
721,240 |
|
- |
|
| Laumas Sandeep |
10% Owner |
– – • |
2022-01-11 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
636,008 |
|
- |
|
24 Records found
|
1
|
Page 1 of 1 |
|
|
